Clinical Trial Evidence Informing Efficacy and Safety of Fda-Approved Treatments in Relapsed and Refractory Multiple Myeloma (RRMM) for Patients (Pts) After Quadruple-Class Exposure (Qcex) (IMS 2026) - Sep 11, 2026 - Abstract #PA-100; Pres time: Sep 25, 2026; " QCEx RRMM subgroups from 8 single-arm trials were identified; 7 investigated 4 BCMA-targeting therapies (cilta-cel, CARTITUDE-2 [n=20]; ide-cel, KarMMa [n=28]; elranatamab, MagnestisMM-1/2/3/9 [n=87]; teclistamab, MajesTEC-1 [n=40]) and 1 investigated a GPRC5D bispecific antibody (BsAb; talquetamab, MonumenTAL-1 [n=75]). This SLR underscores the paucity of approved treatment options and the suboptimal clinical profiles of existing RRMM therapies for pts after QCEx. Anti-BCMA rechallenge was associated with diminished efficacy and high rates of G3-4 toxicity. Among agents evaluated, talquetamab demonstrated the highest response rates and greatest survival, supporting GPRC5D BsAb as a clinically meaningful therapeutic option in this population."
Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia
|
|
Larry Anderson1; Lin Wang2; Karen Chiang3; Leena Patel3; Jaclyn Davis2; Ajai Chari4
|